to-BBB Announces Positive Data From Phase 1 Clinical Study

LEIDEN, Netherlands--(BUSINESS WIRE)--to-BBB, a biopharmaceutical company focusing on treatments for devastating brain diseases, today announced positive clinical data for its product candidate designed to treat neuroinflammation, 2B3-201, from an ongoing Phase 1 clinical trial in healthy volunteers and MS patients. The study was conducted in collaboration with the Center for Human Drug Research (CHDR), Leiden, the Netherlands. The results, presented Thursday, September 11, at the 2014 Joint ACTRIMS-ECTRIMS (Americas Committee and European Committee for Treatment and Research in Multiple Sclerosis) Meeting in Boston, provide evidence that 2B3-201 is safe and well-tolerated at therapeutic dose levels and has a greatly increased plasma half-life and prolonged effects supporting a single administration.

Help employers find you! Check out all the jobs and post your resume.